Cargando…
OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases
Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine with a pleiotropic spectrum of biological functions implicated in the pathogenesis of cancer and inflammatory diseases. MIF is constitutively present in several cell types and non-lymphoid tissues and is secreted after acute...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528626/ https://www.ncbi.nlm.nih.gov/pubmed/36180072 http://dx.doi.org/10.1136/jitc-2022-005475 |
_version_ | 1784801340695773184 |
---|---|
author | Thiele, Michael Donnelly, Seamas C Mitchell, Robert A |
author_facet | Thiele, Michael Donnelly, Seamas C Mitchell, Robert A |
author_sort | Thiele, Michael |
collection | PubMed |
description | Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine with a pleiotropic spectrum of biological functions implicated in the pathogenesis of cancer and inflammatory diseases. MIF is constitutively present in several cell types and non-lymphoid tissues and is secreted after acute stress or inflammation. MIF triggers the release of proinflammatory cytokines, overrides the anti-inflammatory effects of glucocorticoids, and exerts chemokine function, resulting in increased migration and recruitment of leukocytes into inflamed tissue. Despite this, MIF is a challenging target for therapeutic intervention because of its ubiquitous nature and presence in the circulation and tissue of healthy individuals. Oxidized MIF (oxMIF) is an immunologically distinct disease-related structural isoform found in the plasma and tissues of patients with inflammatory diseases and in solid tumor tissues. MIF converts to oxMIF in an oxidizing, inflammatory environment. This review discusses the biology and activity of MIF and the potential for autoimmune disease and cancer modification by targeting oxMIF. Anti-oxMIF antibodies reduce cancer cell invasion/migration, angiogenesis, proinflammatory cytokine production, and ERK and AKT activation. Anti-oxMIF antibodies also elicit apoptosis and alter immune cell function and/or migration. When co-administered with a glucocorticoid, anti-oxMIF antibodies produced a synergistic response in inflammatory models. Anti-oxMIF antibodies therefore counterregulate biological activities attributed to MIF. oxMIF expression has been observed in inflammatory diseases (eg, sepsis, psoriasis, asthma, inflammatory bowel disease, and systemic lupus erythematosus) and oxMIF has been detected in ovarian, colorectal, lung, and pancreatic cancers. In contrast to MIF, oxMIF is specifically detected in plasma and/or tissues of diseased patients, but not in healthy individuals. Therefore, as a druggable isoform of MIF, oxMIF represents a potential new therapeutic target in inflammatory diseases and cancer. Fully human, monoclonal anti-oxMIF antibodies have been shown to selectively bind oxMIF in preclinical and phase I studies; however, additional clinical assessments are necessary to validate their use as either a monotherapy or in combination with standard-of-care regimens (ie, immunomodulatory agents/checkpoint inhibitors, anti-angiogenic drugs, chemotherapeutics, and glucocorticoids). |
format | Online Article Text |
id | pubmed-9528626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-95286262022-10-04 OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases Thiele, Michael Donnelly, Seamas C Mitchell, Robert A J Immunother Cancer Review Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine with a pleiotropic spectrum of biological functions implicated in the pathogenesis of cancer and inflammatory diseases. MIF is constitutively present in several cell types and non-lymphoid tissues and is secreted after acute stress or inflammation. MIF triggers the release of proinflammatory cytokines, overrides the anti-inflammatory effects of glucocorticoids, and exerts chemokine function, resulting in increased migration and recruitment of leukocytes into inflamed tissue. Despite this, MIF is a challenging target for therapeutic intervention because of its ubiquitous nature and presence in the circulation and tissue of healthy individuals. Oxidized MIF (oxMIF) is an immunologically distinct disease-related structural isoform found in the plasma and tissues of patients with inflammatory diseases and in solid tumor tissues. MIF converts to oxMIF in an oxidizing, inflammatory environment. This review discusses the biology and activity of MIF and the potential for autoimmune disease and cancer modification by targeting oxMIF. Anti-oxMIF antibodies reduce cancer cell invasion/migration, angiogenesis, proinflammatory cytokine production, and ERK and AKT activation. Anti-oxMIF antibodies also elicit apoptosis and alter immune cell function and/or migration. When co-administered with a glucocorticoid, anti-oxMIF antibodies produced a synergistic response in inflammatory models. Anti-oxMIF antibodies therefore counterregulate biological activities attributed to MIF. oxMIF expression has been observed in inflammatory diseases (eg, sepsis, psoriasis, asthma, inflammatory bowel disease, and systemic lupus erythematosus) and oxMIF has been detected in ovarian, colorectal, lung, and pancreatic cancers. In contrast to MIF, oxMIF is specifically detected in plasma and/or tissues of diseased patients, but not in healthy individuals. Therefore, as a druggable isoform of MIF, oxMIF represents a potential new therapeutic target in inflammatory diseases and cancer. Fully human, monoclonal anti-oxMIF antibodies have been shown to selectively bind oxMIF in preclinical and phase I studies; however, additional clinical assessments are necessary to validate their use as either a monotherapy or in combination with standard-of-care regimens (ie, immunomodulatory agents/checkpoint inhibitors, anti-angiogenic drugs, chemotherapeutics, and glucocorticoids). BMJ Publishing Group 2022-09-30 /pmc/articles/PMC9528626/ /pubmed/36180072 http://dx.doi.org/10.1136/jitc-2022-005475 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Thiele, Michael Donnelly, Seamas C Mitchell, Robert A OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases |
title | OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases |
title_full | OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases |
title_fullStr | OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases |
title_full_unstemmed | OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases |
title_short | OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases |
title_sort | oxmif: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528626/ https://www.ncbi.nlm.nih.gov/pubmed/36180072 http://dx.doi.org/10.1136/jitc-2022-005475 |
work_keys_str_mv | AT thielemichael oxmifadruggableisoformofmacrophagemigrationinhibitoryfactorincancerandinflammatorydiseases AT donnellyseamasc oxmifadruggableisoformofmacrophagemigrationinhibitoryfactorincancerandinflammatorydiseases AT mitchellroberta oxmifadruggableisoformofmacrophagemigrationinhibitoryfactorincancerandinflammatorydiseases |